Targeted cancer therapy and mechanisms of resistance / / edited by Valentina de Falco.
Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for ca...
Saved in:
TeilnehmendeR: | |
---|---|
Place / Publishing House: | Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022. |
Year of Publication: | 2022 |
Language: | English |
Physical Description: | 1 online resource (x, 268 pages) :; illustrations |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
id |
993562212004498 |
---|---|
ctrlnum |
(CKB)4920000001372273 (NjHacI)994920000001372273 (EXLCZ)994920000001372273 |
collection |
bib_alma |
record_format |
marc |
spelling |
Targeted cancer therapy and mechanisms of resistance / edited by Valentina de Falco. Basel : MDPI - Multidisciplinary Digital Publishing Institute, 2022. 1 online resource (x, 268 pages) : illustrations text txt rdacontent computer c rdamedia online resource cr rdacarrier Description based on publisher supplied metadata and other sources. Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs. In English. Cancer Treatment. Cancer Treatment Complications. 3-0365-2856-3 de Falco, Valentina, editor. |
language |
English |
format |
eBook |
author2 |
de Falco, Valentina, |
author_facet |
de Falco, Valentina, |
author2_variant |
f v d fv fvd |
author2_role |
TeilnehmendeR |
title |
Targeted cancer therapy and mechanisms of resistance / |
spellingShingle |
Targeted cancer therapy and mechanisms of resistance / |
title_full |
Targeted cancer therapy and mechanisms of resistance / edited by Valentina de Falco. |
title_fullStr |
Targeted cancer therapy and mechanisms of resistance / edited by Valentina de Falco. |
title_full_unstemmed |
Targeted cancer therapy and mechanisms of resistance / edited by Valentina de Falco. |
title_auth |
Targeted cancer therapy and mechanisms of resistance / |
title_new |
Targeted cancer therapy and mechanisms of resistance / |
title_sort |
targeted cancer therapy and mechanisms of resistance / |
publisher |
MDPI - Multidisciplinary Digital Publishing Institute, |
publishDate |
2022 |
physical |
1 online resource (x, 268 pages) : illustrations |
isbn |
3-0365-2856-3 |
callnumber-first |
R - Medicine |
callnumber-subject |
RC - Internal Medicine |
callnumber-label |
RC270 |
callnumber-sort |
RC 3270.8 T374 42022 |
illustrated |
Illustrated |
dewey-hundreds |
600 - Technology |
dewey-tens |
610 - Medicine & health |
dewey-ones |
616 - Diseases |
dewey-full |
616.99406 |
dewey-sort |
3616.99406 |
dewey-raw |
616.99406 |
dewey-search |
616.99406 |
work_keys_str_mv |
AT defalcovalentina targetedcancertherapyandmechanismsofresistance |
status_str |
n |
ids_txt_mv |
(CKB)4920000001372273 (NjHacI)994920000001372273 (EXLCZ)994920000001372273 |
carrierType_str_mv |
cr |
is_hierarchy_title |
Targeted cancer therapy and mechanisms of resistance / |
author2_original_writing_str_mv |
noLinkedField |
_version_ |
1764990041515360256 |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02714nam a2200313 i 4500</leader><controlfield tag="001">993562212004498</controlfield><controlfield tag="005">20230223203734.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230223s2022 sz a o 000 0 eng d</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/books978-3-0365-2856-4</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000001372273</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994920000001372273</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000001372273</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC270.8</subfield><subfield code="b">.T374 2022</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616.99406 </subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Targeted cancer therapy and mechanisms of resistance /</subfield><subfield code="c">edited by Valentina de Falco.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (x, 268 pages) :</subfield><subfield code="b">illustrations</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on publisher supplied metadata and other sources.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Tumor cells commonly exhibit dependence on a single activated oncogenic pathway or protein to maintain their malignant proliferation and survival, a phenomenon called "oncogene addiction". According to this concept, protein kinases have been identified as promising molecular targets for cancer therapy. There are several possibilities for targeting these proteins in cancer, including monoclonal antibodies, compounds able to favor the proteolytic degradation of the kinase, small-molecule protein kinase inhibitors (PKIs). Moreover, new anticancer treatments have increasingly been developed focusing on tumor suppressor genes and RNA interference. Despite promising results in cancer treatment with targeted cancer drugs, clinical experience has shown that only a fraction of patients respond to targeted therapies, even if their tumor expresses the altered target. This is known as primary resistance. Otherwise, secondary or acquired resistance to the treatment arises, almost invariably, when tumors are treated with cancer drugs. We set out to select some studies containing emerging developments on the subject. In essence, this collection aims to highlight some recent findings regarding resistance mechanisms and reviews of molecular targeting and resistance with 14 contributions, including 10 original research papers and 4 reviews. Aspects relating to solid cancers, such as breast, ovary, colon, and blood cancers such as leukemia, and the identification of resistance mechanisms and new molecular targets, help to create the basis for the preclinical and clinical development of more effective next-generation drugs.</subfield></datafield><datafield tag="546" ind1=" " ind2=" "><subfield code="a">In English.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Treatment.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Cancer</subfield><subfield code="x">Treatment</subfield><subfield code="x">Complications.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-2856-3</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">de Falco, Valentina,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-01 00:40:04 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338078700004498&Force_direct=true</subfield><subfield code="Z">5338078700004498</subfield><subfield code="8">5338078700004498</subfield></datafield></record></collection> |